Welcome to our dedicated page for Cyclacel Phar Pr SEC filings (Ticker: CYCCP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bio Green Med Solution, formerly Cyclacel Pharmaceuticals, files regulatory reports that document a completed shift from a clinical-stage biopharmaceutical issuer to a diversified company engaged primarily in fire safety protection and distribution activities. The filings describe the acquisition of Fitters Sdn. Bhd., the liquidation of the former U.K. subsidiary, and the sale of the Plogosertib drug.
Its SEC record also includes Form 8-K disclosures on operating results, Regulation FD materials, quarterly cash dividend declarations on 6% Convertible Exchangeable Preferred Stock, Nasdaq listing-rule notices for the preferred stock, and proxy materials for annual-meeting governance and shareholder voting matters.
Cyclacel Pharmaceuticals (CYCCP) filed a DEFA14A Amendment No. 1 to its 2025 proxy statement.
The sole revision corrects total shares outstanding on the May 1, 2025 record date from 381,202,294 to 356,357,531. No other sections, proposals or compensation disclosures were modified. All previously distributed proxy materials and voting matters remain unchanged for the virtual annual meeting scheduled on June 30, 2025.
Cyclacel Pharmaceuticals, Inc. (CYCC/CYCCP) filed an 8-K announcing a private placement of Series F Convertible Preferred Stock and accompanying warrants that closed on 20 June 2025. The company entered into a Securities Purchase Agreement with accredited investors for 3 million shares of Series F Preferred Stock at $1.00 per share, generating $3.0 million in gross proceeds to be used for general corporate and operating purposes.
Dilution mechanics: Each preferred share converts into 3.27 common shares, implying an effective conversion price of roughly $0.31 per common share. Full conversion would create up to ≈9.81 million new common shares, subject to a 4.99 % ownership cap per investor until stockholder approval is obtained. In addition, investors received 29.43 million five-year warrants split into three tranches with exercise prices of $0.51 (Series A), $0.60 (Series B) and $0.68 (Series C) per share. The warrants and preferred shares were issued under Regulation S and are therefore unregistered.
Governance & rights: The Series F Preferred votes with common stock on an as-converted basis (subject to the ownership cap), participates in common dividends, and carries a $1.00 per-share liquidation preference pari passu with other preferred stock. The company has committed to seek stockholder approval for the full issuance of common shares underlying the preferred and the warrants to comply with Nasdaq rules.
Key implications: The financing provides near-term liquidity but introduces the potential for significant future share dilution—up to ~39.2 million additional common shares if all instruments are exercised/converted. Investor approval risk, dilution magnitude, and relatively low effective conversion price are material considerations for existing shareholders.